Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Denovo gains all rights from Lilly to develop, manufacture and commercialize enzastaurin drug

Denovo Biopharma, LLC, today announced that it has acquired enzastaurin, a late-stage oncology drug, from Eli Lilly and Company. Denovo gains all rights to develop, manufacture and commercialize enzastaurin globally, including transfer of all intellectual property and other rights, data, and information.

16 Sep 2014

Blocking bacteria's access to iron: an interview with Dr. Laxminarayana Devireddy

Iron is a key nutrient for nearly all living organisms, including bacteria. Iron is a cofactor for many enzymes necessary for basic metabolic reactions such as DNA synthesis and electron transport. Iron serves as the conduit for the electron transport chain that generates the energy necessary to drive the bacterial cell.

16 Sep 2014

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie today announced results from a Phase 3 pivotal study demonstrating that HUMIRA® (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules.

11 Sep 2014

New immuno-oncology drug helps body's own immune system to fend off cancer

According to an August 25 Reuters report, the U.S. Food and Drug Administration is likely to approve Merck & Co.'s highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline.

8 Sep 2014

Scientists identify how immune cells use two critical receptors to clear dead cells from the body

In most of the tissues of the body, specialized immune cells are entrusted with the task of engulfing the billions of dead cells that are generated every day.

8 Sep 2014

New antifungal drug effective against invasive mold disease in cancer patients with less adverse effects

A newly developed antifungal, isavuconazole, is as effective as an existing drug, voriconazole, against invasive mold disease in cancer patients with less adverse effects, according to phase 3 clinical data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, an infectious disease meeting of the American Society for Microbiology.

8 Sep 2014

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the acquisition of a novel orphan drug candidate, known as SGX301 (synthetic hypericin).

8 Sep 2014

Longer looks: Alzheimer's and a marriage; racism in medicine; abortion restrictions in Texas

The US, which has a mostly private health-care system, manages to spend more on its public health-care system than countries where the health-care system is almost entirely public. America's government spends more, as a percentage of the economy, on public health care than Canada, the United Kingdom, Japan or Australia. And then it spends even more than that on private health care.

5 Sep 2014

Infinity and AbbVie enter into global collaboration to develop and commercialize duvelisib

Infinity Pharmaceuticals, Inc. and AbbVie Inc. today announced that they have entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of patients with cancer.

3 Sep 2014

Organizations across U.S. participating in Go Gold for Childhood Cancer Awareness campaign

Organizations in Atlanta – and across the country – are participating in the Go Gold for Childhood Cancer Awareness campaign this September. Coordinating this effort is the Aflac Cancer Center of Children's Healthcare of Atlanta along with the Stop Childhood Cancer Alliance that was created to be the driving force in increasing awareness of childhood cancer and enhancing support for the young people fighting this disease, as well as the clinicians and researchers helping them.

2 Sep 2014

Researchers find method to expand blood stem cells used to treat cancer patients

A team of scientists from the University of Colorado School of Medicine has reported the breakthrough discovery of a process to expand production of stem cells used to treat cancer patients.

30 Aug 2014

Researchers develop new integrated approach to pinpoint genetic "drivers" of cancer

UNC Lineberger Comprehensive Cancer Center researchers have developed a new integrated approach to pinpoint the genetic "drivers" of cancer, uncovering eight genes that could be viable for targeted breast cancer therapy.

25 Aug 2014

Statistical genetic analysis can detect aggressiveness of lymphoma

Each year, more than one thousand Norwegians develop lymphoma. A statistical genetic analysis can detect when the disease will be aggressive. Thereby, treatment can be initiated in time.

25 Aug 2014

Researchers identify mutated forms of gene that encodes unregulated enzyme driving CML

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have identified and characterized mutated forms of the gene that encodes BCR-ABL, the unregulated enzyme driving the blood cancer chronic myeloid leukemia (CML).

21 Aug 2014

Dasatinib: Leukemia drug shows promise for treating skin, breast and other cancers

A leukemia drug called dasatinib shows promise for treating skin, breast and several other cancers, according to researchers at Loyola University Chicago Stritch School of Medicine.

20 Aug 2014

Natural killer cells can be used to combat acute lymphoblastic leukemia

Researchers at Children's Hospital Los Angeles have shown that a select team of immune-system cells from patients with leukemia can be multiplied in the lab, creating an army of natural killer cells that can be used to destroy the cancer cells.

19 Aug 2014

Lymphocyte count predicts papillary RCC patient survival

Lymphopenia is a significant predictor of outcome in patients undergoing surgery for papillary renal cell carcinoma, US researchers report.

18 Aug 2014

Research findings may lead to novel target for chemoresistant cancer cells

Dartmouth cancer researchers at Norris Cotton Cancer Center found a means of causing the elimination of a protein that maintains cancer cell viability; the results of the study appear in the August 8 issue of The Journal of Biological Chemistry.

17 Aug 2014

Researchers find method to repair gene mutation causing autoimmune deficiency disease

Researchers at Karolinska Institutet in Sweden have found a method to repair the gene mutation causing agammaglobulinemia, an autoimmune deficiency disease that almost exclusively affects boys and in which the body lacks the ability to produce immunoglobulins (gamma globulin).

14 Aug 2014

Study exposes racial differences in the treatment of lymphoma

A new study published in a leading scientific journal has shown race can have a detrimental effect on medical treatment offered by doctors.

12 Aug 2014

Lymphoma News and Research

Further Reading

Denovo gains all rights from Lilly to develop, manufacture and commercialize enzastaurin drug

Blocking bacteria's access to iron: an interview with Dr. Laxminarayana Devireddy

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

New immuno-oncology drug helps body's own immune system to fend off cancer

Scientists identify how immune cells use two critical receptors to clear dead cells from the body

New antifungal drug effective against invasive mold disease in cancer patients with less adverse effects

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Longer looks: Alzheimer's and a marriage; racism in medicine; abortion restrictions in Texas

Infinity and AbbVie enter into global collaboration to develop and commercialize duvelisib

Organizations across U.S. participating in Go Gold for Childhood Cancer Awareness campaign

Researchers find method to expand blood stem cells used to treat cancer patients

Researchers develop new integrated approach to pinpoint genetic "drivers" of cancer

Statistical genetic analysis can detect aggressiveness of lymphoma

Researchers identify mutated forms of gene that encodes unregulated enzyme driving CML

Dasatinib: Leukemia drug shows promise for treating skin, breast and other cancers

Natural killer cells can be used to combat acute lymphoblastic leukemia

Lymphocyte count predicts papillary RCC patient survival

Research findings may lead to novel target for chemoresistant cancer cells

Researchers find method to repair gene mutation causing autoimmune deficiency disease

Study exposes racial differences in the treatment of lymphoma

Everything you should know about lymphoma eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News